John Carroll

Biography for John Carroll

John D. Carroll, Editor-in-Chief

John D. Carroll is a biotech analyst with 36 years of experience in journalism that’s taken him all over the world--and back again. Appointed editor of FierceBiotech in 2003, he has covered everything from city hall in Kansas City, KS, to biotech in London. He contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and a medley of other publications. He spent six years as editor and then publisher of the Dallas Business Journal, was publisher of Texas Business for a brief stint and early in his career was part of a big team of reporters and editors at the Kansas City Star & Times that investigated the deadly 1981 disaster at a local Hyatt Regency. The newspapers won a 1982 Pulitzer for their collective work. Carroll lives in Vermont and travels frequently. He can be reached at Follow @JohnCFierce on Twitter.

Articles by John Carroll

Intercell scrambles after vax patch flunks PhII

Startled by the unexpected failure of a mid-stage trial of its vaccine adjuvant patch, Intercell AG is changing up the vaccine it used in the study along with the hemagglutinin inhibition assay used

Dynavax launches first human trial of universal flu vax

Dynavax (NASDAQ: DVAX) has been busy over the last few days. The Berkeley, CA-based vaccine developer says it has begun dosing its first patients in a Phase I trial of its experimental universal flu

Dendreon shares routed by Medicare Provenge review news

Shares of Dendreon (DNDN) took a nasty hit on Wednesday after Medicare officials announced plans to review its new prostate cancer vaccine to see whether the federal program should pay to provide it

Up to 70M doses of unused H1N1 vax to be destroyed

With the great swine flu pandemic of 2009 largely forgotten by the U.S. public, health officials say they are preparing to burn 40 million doses of expired H1N1 vaccine they bought to guard the

New meningitis vax arrives in Africa

A newly approved meningitis vaccine developed by an international consortium that includes Bill Gates and the WHO is being deployed as the first line of defense against the meningitis epidemics that

Theraclone makes a breakthrough on universal flu vax

Seattle-based Theraclone Sciences says that a team of scientists in its own ranks working in league with researchers from around the world have zeroed in on rare antibodies that have the ability to

Injector tech could slash polio vaccine costs

A new needle-free injector technology that can deliver vaccine just under the skin among infants can provide a protective amount of polio vaccine with only a fifth of the recommended dosage.

Synthetic flu virus opens door to safer vaccines

A group of molecular biologists and computer scientists at Stony Brook University have created a synthetic flu virus that can be used to develop a safer type of vaccine. The

Crucell decides to tackle universal RSV vaccine project

When Johnson & Johnson handed over €302 million for an 18 percent stake in Crucell last year, the two companies signed off on an ambitious new vaccines venture, with the Dutch biotech

Pfizer plans to shutter one vax plant, beef up another

Pfizer (NYSE: PFE) isn't just cutting manufacturing ops in the wake of its merger with Wyeth. The pharma giant is actually adding to its staff at its facility in Lincoln, NE, which develops and